PAGE 1 OF 7 PAGES Amendment No. 23

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

and	and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.						
Licensee  1. Radiopharmacy Incorporated				In accordance with letter dated March 25, 2020,		4. Expiration Date: June 30, 2021	
2.	1409 East Virginia Street Evansville, IN 47711		S		13-26246-01MD in its entirety to read		ret No.: 030-31910 rence No.:
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and/or physical f	form 8.	Maximum amount that licens may possess at any one time under this license		Authorized use
A.	Any byproduct material with Atomic Nos. 1 through 83 with exceptions	A.	Any S	A	1000 millicuries total	A.	Preparation and distribution of radioactive drugs, including compounding of iodine-131 and redistribution of unused molybdenum-99/technetium-99m generators, to authorized recipients in accordance with 10 CFR 32.72. Preparation and distribution of radioactive drugs and radiochemicals, including compounding of iodine-131 and redistribution of unused molybdenum-99/technetium-99m generators, to authorized recipients for non-medical use.
В.	Molybdenum-99	B.	Any	В.	100 curies total	B.	Same as Item 9.A.
C.	Technetium-99m	C.	Any	C.	100 curies total	C.	Same as Item 9.A.

NRC FORM 374A				U.S. NUCLEAR REGULATORY COMMISSION			SSION	PAGE <sup>3</sup> OF <sup>7</sup> PAGES		
MATERIALS LICENSE					Docket or Reference No. 030-31910		).			
SUPPLEMENTARY SHEET				Amendment No. 23						
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and	l/or physical form	8. <b>P</b>	Maximum amo may possess a under this licen		9.	Authorized use	
l.	Radium-223	I.	Liquid	AUCLEAR	I.	5 millicuries to	otal	I.	For the preparation, distribution, and redistribution of radium-223 dichloride radioactive drugs to authorized recipients.	
J.	Germanium-68	J.	Any	SU	J.	100 millicuries	s total	J.	For use of the Eckert and Ziegler GalliaPharm™ and IRE Galli-Eo® Ge-68/Ga-68 generators to prepare Ga-68 radiopharmaceuticals for imaging and localization studies.	
K.	Gallium-68	K.	Any		K.	100 millicuries	s total	K.	For preparation and distribution of radioactive drugs in accordance with 10 CFR 32.72 and radiochemicals for non-medical use to authorized recipients.	
CONDITIONS										
10. Licensed material shall be used or stored only at the licensee's facilities located at 1409 East Virginia Street, Evansville, Indiana, 47711.										
11. A. Licensed material shall only be used by, or under the supervision of:										
	1) A pharmacist working or designated as an authorized nuclear pharmacist in accordance with 10 CFR 32.72(b)(2)(i) or (4).									

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION	PAGE 4 OF 7 PAGES
MATERIALS LICENSE	License No. 13-26246-01MD	Docket or Reference No. 030-31910	
SUPPLEMENTARY SHEET	Amendment No. 23		

2) Authorized Nuclear Pharmacists:

Alexander J. Bassemier, PharmD E. Dean Dome, R.Ph. Bynum L. Kimmons, R.Ph. Nicole M. Spurling, R.Ph. Jason J. Wilson, R.Ph. Matthew O. Broshears, R.Ph John E. Haney, R.Ph. Kyle Kuczmanski, PharmD John Vardsveen, PharmD

Andrew Scott Day, R.Ph. Phillip B. Harris, R.Ph. Timothy M. Quinton, R.Ph. Ruth Mary Wetzel, R.Ph.

- B. The Radiation Safety Officer (RSO) for this license is Jason J. Wilson, R.Ph.
- 12. A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed six months, or at such other intervals as specified.
  - B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
  - C. Sealed sources need not be tested if they contain only hydrogen 3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
  - D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMI	SSION	PAGE 5 OF 7 PAGES
MATERIALS LICENSE	License No. 13-26246-01MD	Docket or Reference No. 030-31910	
SUPPLEMENTARY SHEET	Amendment No. 23		

- E. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
- F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for three years.
- 13. Sealed sources containing licensed material shall not be opened.
- 14. The licensee shall conduct a physical inventory every six months to account for all sources and/or devices received and possessed under the license.
- 15. The licensee is authorized to hold radioactive material with a physical half-life of less than or equal to 120 days for decay-in-storage before disposal in ordinary trash provided:
  - A. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated, except for radiation labels on materials that are within containers and that will be managed as biomedical waste after they have been released from the licensee.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	ISSION	PAGE 6 OF 7 PAGES
MATERIALS LICENSE	License No. 13-26246-01MD	Docket or Reference No. 030-31910	
SUPPLEMENTARY SHEET	Amendment No. 23		

- B. A record of each such disposal permitted under this license condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.
- 16. The licensee is authorized to retrieve, receive and dispose of radioactive waste from its customers limited to radiopharmacy supplied syringes and vials and their contents.
- 17. Notwithstanding the requirements of 10 CFR 30.35(a)(1), the licensee is exempt from the requirement to have a decommissioning funding plan needed for the possession and use of Ge-68/Ga-68 medical use generators (Eckert and Ziegler GalliaPharm™ and IRE Galli-Eo® generators), based on the commitments between the licensee and manufacturer (Eckert and Ziegler for the GalliaPharm™) and between the licensee and distributor (Cardinal Health for the Galli-Eo®). The licensee shall return the generators to the manufacturer/distributor in accordance with the generator return agreements described in the letters dated August 26, 2019 (ML19240B407) and October 2, 2019 (ML19275G305).

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	SSION	PAGE 7 OF 7 PAGES
MATERIALS LICENSE	License No. 13-26246-01MD	Docket or Reference No. 030-31910	
SUPPLEMENTARY SHEET	Amendment No. 23		
<ol> <li>Except as specifically provided otherwise representations, and procedures contained those procedures that are required to be regulations shall govern unless the stater more restrictive than the regulations.</li> <li>A. Application dated February 15, 2011</li> </ol>	ed in the documents, including any enclosubmitted in accordance with the regulaments, representations, and procedures	osures, listed below. This license attions. The U.S. Nuclear Regulato	condition applies only to ry Commission's
B. Letter dated March 7, 2014 (ML1406		2	
C. Letter dated October 27, 2016 (ML16		C	
D. Letter dated December 16, 2016 (MLE. Letter dated August 26, 2019 (ML192		9	
F. Letter dated October 2, 2019 (ML192 G. Letter dated November 20, 2019 (ML	75G305) 19324G109)	MASSIMA	
	FOR	THE U.S. NUCLEAR REGULATO	RY COMMISSION
Date: <u>April 16, 2020</u>		ryan A. Parker legion III	